Skip to main content
OpenTrials
Completed

NCT Number: NCT01496391

A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function

Iodine-123 labelled ortho-Iodohippuric Acid ([I-123]-OIH) was used in the early 1970's as a kidney imaging agent or tracer that "lights-up" inside your body when scanned, but over the years its use has declined. The most commonly used tracer is Technetium-99m labelled Mercaptoacetyltriglycine ([Tc-99m]-Mertiatide or [Tc-99m]-MAG3). However, long-term shortages may threaten the supply of the radioactive substance Tc-99m in Canada and the world. As a result of such shortages, there is a need to identify other types of tracers that can be used for imaging. [I-123]-OIH may be an alternative.

The purpose of this study is to examine the diagnostic performance characteristics of [I-123]-OIH in comparison to [Tc-99m]-MAG3.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

St. Joesph's Healthcare Hamilton

Hamilton, Ontario, L8N 4A6, Canada

About this study

This study is being conducted to compare two imaging agents (tracers): [I-123]-OIH and [Tc-99m]-MAG3 using gamma camera imaging in participants with different levels of kidney function. Gamma camera imaging is a non-invasive nuclear scan that is used to look at organs and tissues inside the body. An imaging agent or tracer is a radioactive chemical intravenously injected into your body which lights up cells, tissues and organs. The study will evaluate the safety of a single injection of [I-123]-OIH and compare the imaging results and the calculated renal function values (using blood tests) to those of [Tc-99m]-MAG3 . 90 participants are required to complete this study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age.
  • Provide signed informed consent.
  • Documented stable renal impairment with an eGFR < 60/mL/min/1.73m^2 by two eGFR measurements within 3 months that are within ± 15% of each other or healthy prospective kidney donor with an eGFR ≥ 60 mL/min/1.73m^2.

Exclusion criteria

  • Females who are pregnant, planning to become pregnant or are lactating.
  • Clinically relevant abnormal findings that could, in the opinion of the investigator, interfere with the safe completion of the study.
  • Unable, in the opinion of the clinician or investigator, to tolerate fluid intake required for radionuclide renography.
  • Participation in any clinical trial involving an investigational product within 30 days prior to the first injection.
  • Not using an adequate method of family planning unless the participant, or the male participant's partner, has had a hysterectomy, a tubal ligation, is postmenopausal or is not at risk of pregnancy.
  • Unable to lie still in a supine position for at least 30 minutes.
  • Unable to complete study procedures, including follow-up safety assessments.
  • Medical or psychological conditions that on assessment by the principal investigator make the participant unable to complete the procedure.
  • History of allergic reaction to iodine or iodine compounds, inclusive of iodinated x-ray contrast media.
  • Any other conditions that may impact the participant's ability to complete the study.

Treatment and study plan

Primary outcomes

  1. [I-123]-OIH Safety

    Time frame: Visit 3 and Follow-up Phone Call

    Evaluate the safety of a single injection of [I-123]-OIH administered to a population of healthy prospective kidney donors and patients with stable chronic renal impairment.

  2. Compare kidney function using [I-123]-OIH and [Tc-99m]-MAG3 imaging

    Time frame: Visit 2 and 3

    Compare results of renal plasma flow derived from [I-123]-OIH and [Tc-99m]-MAG3 gamma camera images of healthy prospective kidney donors and patients with stable chronic renal impairment.

Secondary outcomes

  1. Qualitative Assessment

    Time frame: Visit 2 and 3

    Compare the qualitative assessment of kidney uptake, urine excretion and image quality of [I-123]-OIH and [Tc-99m]-MAG3 in an independent read by two nuclear medicine physicians blinded to all participant clinical data.

  2. Image-derived Perfusion Data

    Time frame: Visits 2 and 3

    Compare results of differential perfusion(from image-derived perfusion data) of [I-123]-OIH and [Tc-99m]-MAG3.

  3. eRPF

    Time frame: Visits 2 and 3

    Compare results of effective renal plasma flow (eRPF), using the single sample clearance method of [I-123]-OIH and [Tc-99m]-MAG3.

Sponsors and collaborators

Lead sponsor

Centre for Probe Development and Commercialization

Other

Collaborators

  • McMaster University
  • St. Joseph's Healthcare Hamilton

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
Dec 21, 2011
Registry last updated
Apr 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.